Date: Thursday 15 May 2025
Time: 14:00 – 15:00 CET
Location: Online
We recently took stock of the first 100 days of the EU Joint Clinical Assessment (JCA) in our latest webinar. Our panel shared key observations from the initial rollout, discussed how stakeholders have been preparing, and explored what may lie ahead for companies navigating this evolving landscape.
By attending this webinar, you will
Gained an understanding of the current status of the EU Joint Clinical Assessment process, including timelines, procedural developments, and how Member States have engaged so far.
Gained clarity on the practical steps biopharma companies have taken (and can still take) to prepare for EU HTA submissions amid ongoing uncertainty.
Explored the role of Joint Scientific Consultations (JSCs) in aligning regulatory and HTA evidence generation, and how biopharma companies have engaged with the process.
Examined the initial scope and implications of the first planned assessments, with a focus on Oncology and Advanced Therapy Medicinal Products (ATMPs).
Identified key areas of alignment and divergence between EU HTA and national processes — and considered what this means for market access strategies.
Speakers
Please note, this webinar recording is exclusively available for biopharma companies.
Be part of the conversation – register now to explore the early signals, strategic considerations, and what’s coming next for EU HTA.
Kintiga (formerly MAP Patient Access, AxTalis & SKC) is Europe’s leading independent specialist pharmaceutical and biotechnology management consultancy. Our mission is to partner with health technology developers to elevate client capabilities and expand European market access.
We provide strategic consulting services to optimise market access, commercialisation, and regulatory success, ensuring innovative treatments reach more European patients faster.
Our varied webinar programme aims to shine a spotlight on key developments in the market access sphere and share actionable approaches to alleviate some of the pain points that health technology developers face in their everyday work.
